ABI
MRK icon

Adamant Biomedical Investments’s Merck MRK Stock Holding History

Adamant Biomedical Investments’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$2.27M Hold
41,920
– – 0.54% 60
2014
Q3 		$2.37M Buy
+41,920
New +$2.35M 0.59% 55

Other funds holding MRK

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adamant Biomedical Investments's MRK Position: Q4 2014 in Review

Adamant Biomedical Investments held its Merck (MRK) position steady in Q4 2014 at 41,920 shares worth $2.27M. The position accounts for 0.54% of the portfolio, ranked #60.

Adamant Biomedical Investments first reported a position in MRK in Q3 2014 and has held it in 2 quarters since. The position peaked at $2.37M in Q3 2014. 1,722 funds tracked by Wall St. Rank hold MRK as of Q4 2014.

  • Adamant Biomedical Investments held 41,920 shares of Merck worth $2.27M as of Q4 2014.
  • Adamant Biomedical Investments left its Merck share count unchanged in Q4 2014.
  • Merck made up 0.54% of Adamant Biomedical Investments's portfolio in Q4 2014, its #60 holding.
  • Adamant Biomedical Investments first reported a position in Merck in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Merck position peaked at $2.37M in Q3 2014.
  • 1,722 funds tracked by Wall St. Rank held Merck as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.